Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
B. Riley, Foghorn Therapeutics
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology
B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for tumor treatment. Read more here.
Foghorn Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers
B. Riley Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation
Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with a Buy recommendation. Analyst Price Forecast Suggests 207.54% Upside As of January 28,
Hosted on MSN
9d
Bottom 100 Stocks to Buy: Is B. Riley Financial Uninvestable?
The markets were closed on Monday for Martin Luther King Jr. Day, which also marked the inauguration of Donald J. Trump, the ...
13h
What is B. Riley’s Forecast for CUBI Q1 Earnings?
B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...
2d
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...
8d
on MSN
B. Riley Financial suspends dividends on preferred shares, plans to pay off notes
B. Riley Financial Inc (NASDAQ:RILY). has paused the payment of dividends on two of its preferred stock offerings. The ...
3d
on MSN
B. Riley upgrades Redwire on growth potential from Edge Autonomy acquisition
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
1d
ClearPoint Neuro price target raised to $20 from $15 at B. Riley
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
2d
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
13h
FY2024 EPS Estimates for Ladder Capital Cut by B. Riley
Analysts at B. Riley reduced their FY2024 earnings estimates for shares of Ladder Capital in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst R. Binner now ...
9d
B. Riley Suspends Preferred Payouts Ahead of Note Redemption
B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback